Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Up 228.5% in December

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totalling 497,000 shares, an increase of 228.5% from the November 30th total of 151,300 shares. Currently, 5.6% of the company’s stock are short sold. Based on an average trading volume of 1,660,000 shares, the days-to-cover ratio is presently 0.3 days.

Windtree Therapeutics Price Performance

Shares of WINT opened at $0.31 on Thursday. The firm has a fifty day moving average price of $0.57 and a 200 day moving average price of $3.40. The stock has a market cap of $2.79 million, a PE ratio of -0.02 and a beta of 0.54. Windtree Therapeutics has a 1-year low of $0.29 and a 1-year high of $14.75.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “neutral” rating and set a $7.00 target price on shares of Windtree Therapeutics in a research note on Wednesday, December 4th.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.